A spokesperson said the company's move was "part of our efforts to align resources with our long-term strategic goals."

US pharmaceutical giant Gilead has obtained a patent for its Hepatitis C drug from India. This patent could potentially stop affordable copies reaching millions of people in other countries.

The government said it's distributing the promising coronavirus drug, remdesivir, to some hard-hit states. Eventually, all 50 states should get it.

The US government began distributing remdesivir, an experimental drug recently approved for emergency use against Covid-19, to areas of the country struggling the most with the disease.The Department of Health and Human Services (HHS) arranged for some 600,000 vials of Gilead Sciences’ antiviral medication, shown to reduce recovery times for some patients, to be shipped to health authorities in New Jersey, Illinois, Michigan and three other states, to treat an estimated 78,000 hospitalised…

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United States would receive about 40% of the drug maker's global donation.

An experimental antiviral drug developed by a research-based biopharmaceutical company, Gilead Sciences showed positive results on its application, where more than half of a group of severely ill coronavirus patients improved. UPDATE: On 29 April, Gilead Sciences Inc. announced that in Phase

AP Photo/Alex Brandon

• The federal government on Saturday announced initial plans for distributing a promising coronavirus drug, remdesivir.
• The drug, manufactured by Gilead Sciences, was authorized for emergency use last week, but doctors and hospitals weren't sure how they were going to get it.
• The Department of Health and Human Services now say the drug is first being distributed to health departments in some hard-hit states, and the departments can distribute it to hospitals as they see fit. 
• Eventually, HHS expects the drug to be delivered to all 50 states, terrorities, the Veterans Health Administration and the Indian Health Service. 
• Visit Business Insider's homepage for more stories.

The federal government released its initial distribution plans today for the promising coronavirus drug, remdesivir, which was approved for emergency use last week. 

The drug, donated by manufacturer Gilead Sciences, "will be used to treat hospitalized COVID-19 patients in areas of the country hardest hit by the pandemic," the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) said in a press release.

See the rest of the story at Business Insider

NOW WATCH: How the Navy's largest hospital ship can help with the coronavirus

See Also:

• The coronavirus drug remdesivir was OK'd for emergency use a week ago. The plan to get it to patients is still mired in confusion.
• Dispensed: Hospitals are stuck waiting for a promising coronavirus treatment
• 'It's hard to pay off your medical school loans in this kind of a job': Doctors who can protect the world against pandemics are in short supply

(United States Ninth Circuit) - Reversing the district court's dismissal of claims under the False Claims Act by realtors against their former employer who made false statements about its compliance with FDA regulations regarding certain HIV drugs resulting in the receipt of billions of dollars from the federal government and alleging retaliation against the complaining realtor, holding that the realtors adequately pled a claim for retaliation.

(United States Federal Circuit) - Affirming the judgment that Merck, initially defending its patent on Hepatitis C drugs against a competitor seeking to have them found invalid, who successfully counter-sued for infringement, had unclean hands regarding the patents and was properly barred from asserting its patents and awarded attorney fees to the plaintiff.

(United States Federal Circuit) - Affirming the dismissal of a declaratory judgment action filed against the producer of several antiviral drugs used in the treatment of AIDS by an organization providing medical care to AIDS sufferers seeking to have patents declared invalid because the action failed to meet the requirements of the Declaratory Judgment Act.

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy a treatment for the COVID-19 virus.

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy a treatment for the COVID-19 virus.

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy a treatment for the COVID-19 virus. In one case, a fake email login page designed to steal passwords was sent in April to a top Gilead executive involved in legal and corporate affairs, according to an archived version on a website used to scan for malicious web addresses. Ohad Zaidenberg, lead intelligence researcher at Israeli cybersecurity firm ClearSky, who closely tracks Iranian hacking activity and has investigated the attacks, said the attempt was part of an effort by an Iranian group to compromise email accounts of staff at the company using messages that impersonated journalists.

Regulators on Friday afternoon granted emergency authorization for the Gilead Sciences drug remdesivir as a treatment for patients hospitalized with severe COVID-19 infections. The decision makes the antiviral drug, which is delivered via intravenous infusion, the second drug to receive authorization under the FDA’s emergency guidelines for use against the novel coronavirus. The first was […]

Gilead has said that Dr John McHutchison is stepping down after nine years at the firm.

Gilead’s Chief Scientific Officer and Head of Research and Development has decided to leave the company next month, Gilead said.

Under McHutchinson, Gilead developed five new hepatitis drugs, which have been used by as many as 3.2 million people around the world.

read more

Lilly veteran Christi Shaw has joined Kite Pharma as the company’s new CEO.

Shaw comes to Gilead’s cancer immunotherapy firm, Kite Pharma, from rival US firm Eli Lilly, where she acted as a senior vice president and also as president of Lilly’s immunology, pain and neuroscience unit, Lilly Bio Medicines.

read more

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st.

Dr Parsey will be responsible for and oversee the company’s global clinical development and medical affairs organisations – reporting directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.

read more

Gilead Sciences have announced that Andrew Dickinson has been appointed as Chief Financial Officer (CFO) effective 1 November.

Dickinson currently serves as the company’s Executive Vice President of Corporate Development and Strategy and in his new role will become part of a senior leadership team reporting directly to Chairman and Chief Executive Officer Daniel O’Day.

read more

The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the treatment of patients hospitalised with COVID-19.

Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one of the only therapies to do so at this early stage of the pandemic. Now, the FDA has invoked its Emergency Use Authorization powers to approve the drug for the treatment of patients hospitalised with the novel coronavirus.

New crop of data suggests drug can speed recovery from COVID-19

Move comes after drug showed preliminary efficacy in clinical trial in late April

California’s Gilead Sciences has outlined a plan to ramp up production of newly USA-approved COVID-19…

Gilead Sciences scored a massive win earlier this week with its first positive data readout for investigational candidate remdesivir in treating patients with severe COVID-19. Gilead already has its own supply of the drug humming in anticipation of high demand, but opportunities are out there for a partner to join in. 

Days after U.S. officials reported the first positive controlled data for Gilead's remdesivir in COVID-19, the FDA has given the drug an emergency use authorization.

While Gilead has yet to present a marketing plan for remdesivir—much less a price—ICER figures the COVID-19 drug could be cost-effective at up to $4,460 per patient. That means it could easily rake in blockbuster sales this year, at least theoretically.

The world is waiting for Gilead Sciences to set a price tag for remdesivir, the first brand-new med authorized to treat COVID-19. Its choice will affect Gilead's reputation and bottom line, set a tone for follow-up meds—and either help polish up the pharma industry's image or create a new flashpoint for criticism.

Gilead Sciences' remdesivir, now called Veklury, has won a fast Japanese nod in SARS-CoV-2. The Big Biotech's scouting licensing partners to ramp up supply around the world. Eli Lilly has signed on China's Junshi Biosciences to develop neutralizing antibodies against the novel coronavirus. And more.

Gilead Sciences has captured worldwide attention with its COVID-19 antiviral, remdesivir, cleared late last week by the FDA—not all of it welcome. With bad actors targeting companies at the head of the spear in the pandemic response, Gilead may have found itself in their sights.

The FDA has issued emergency use authorization for Gilead Science Inc's (GILD) antiviral drug Remdesivir for the treatment of COVID-19 in adults and children hospitalized with severe disease.

The European Medicines Agency has begun a rolling review of data on Gilead’s remdesivir, positioning it to cut the time it takes to decide whether to approve the drug in COVID-19 patients.

Ronny Gal of Sanford C. Bernstein says he thinks remdesivir will not be the most significant revenue contributor for Gilead Sciences over time. He also explains his rationale for raising the company's price target to $75 from $72.

Check out the companies making headlines in midday trading.

The stocks making the biggest moves in premarket trading include Berkshire Hathaway, Gilead, Disney, Intel, and more.

Exclusive: Disappointing results revealed in draft documents published accidentally by WHO

Biotech group’s shares have soared this year on hopes drug could be used to treat coronavirus

Gilead Sciences CEO Daniel O'Day wrote in an open letter obtained by Fox News that early results on his company's drug remdesivir's benefits for coronavirus patients offer 'hope' that's badly needed.

Gilead Sciences said Thursday in an earnings report that it is ramping up production of its antiviral remdesivir, and could make 'several million' 10-day treatment courses of the drug for 2021.

Gilead Sciences CEO Daniel O'Day told Stat News that his company understands its responsibility to make its antiviral drug affordable after it showed promise for treating coronavirus.

Gilead Scienced, based in California, said it's in talks with 'several' generic drug makers across Europe and Asia, including India and Pakistan, to produce its experimental coronavirus drug remdesivir.

A report from a cost watchdog estimated that it costs $9.32 to manufacture one 10-day course of remdesivir treatment and that, if proven to save live, it could cost $4,500 per treatment.

Remdesivir is an investigational antiviral drug that may be found effective against the virus that causes Covid-19